Company Profile

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE327.702.75 (+0.85 % )
PREV CLOSE (Rs.) 324.95
OPEN PRICE (Rs.) 327.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 327.70 (59 )
VOLUME 55569
TODAY'S LOW / HIGH (Rs.)322.70 331.60
52 WK LOW / HIGH (Rs.)267.3 706.9
NSE327.65 2.75 (+0.85 % )
PREV CLOSE(Rs.) 324.90
OPEN PRICE (Rs.) 326.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 327.65 (2348 )
VOLUME 1867793
TODAY'S LOW / HIGH(Rs.) 323.00 331.75
52 WK LOW / HIGH (Rs.)267.25 705.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.61
TTM EPS (Rs.) 39.36
P/E Ratio 8.33
Book Value (Rs.) 446.63
Face Value (Rs.) 1
MCap (Rs. in Mn) 92466.50
Price/Earning (TTM) 7.53
Price/Sales (TTM) 1.46
Price/Book (MRQ) 0.73
PAT Margin (%) 23.14
ROCE (%) 15.78
Incorporation Year : 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone :

Registrar's Details : KFIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
26Nov11-26-2019$Glenmark Pharma’s arm gets final USFDA’s nod for Metformin Hydrochloride Extended-Release Tablets Glenmark Pharma’s arm gets

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg, the generic version of Glumetza Extended-Release Tablets, 500 mg and 1000 mg, of Salix Pharmaceuticals Inc.

According to IQVIA sales data for the 12-month period ending September 2019, the Glumetza Tablets, 500 mg and 1000 mg market achieved annual sales of approximately $226.7 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceutic..
26Nov11-26-2019$Glenmark Pharmaceuticals submits media release Glenmark Pharmaceuticals sub

Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg’, which is self explanatory.  

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed about submission of media..
15Nov11-15-2019$Glenmark Pharmaceuticals reports 38% fall in Q2 consolidated net profit Glenmark Pharmaceuticals rep

Glenmark Pharmaceuticals has reported results for second quarter ended September 30, 2019.

The company has reported a fall of 42.21% in its net profit at Rs 432.00 crore for the quarter under review as compared to Rs 747.56 crore for the same quarter in the previous year. However, total income of the company increased by 4.00% at Rs 1982.29 crore for Q2FY20 as compared Rs 1906.02 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a fall of 38.28% in its net profit at Rs 255.54 crore for the quarter under review as compared to Rs 414.00 crore for the same quarter in the previous year. However, total income of the company increased by 6.42% at Rs 2895.87 crore for Q2FY20 as compared Rs 2721.21 crore for the corresponding quarter previous year.

Glenmark Pharmaceuticals has reported results for second quarte..
11Nov11-11-2019$Glenmark recalling around 2.17 lakh cartons of Estradiol Vaginal inserts in US Glenmark recalling around 2.

Glenmark Pharmaceuticals has initiated recalling of close to 2.17 lakh cartons of Estradiol Vaginal inserts in the US market due to faulty delivery system.

As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Glenmark Pharmaceuticals Inc USA is recalling the product in various strengths which was manufactured at the company's Goa manufacturing facility. The ongoing voluntary class II recall is on account of a defective delivery system with complaints for the difficulty in pushing the plunger of the applicator.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals has initiated recalling of close to 2...
11Nov11-11-2019$Glenmark’s arm gets USFDA’s nod for Adapalene and Benzoyl Peroxide Gel Glenmark’s arm gets USFDAâ

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Adapalene and Benzoyl Peroxide Gel, 0.1% 2.5%, the generic version of Epiduo Gel, 0.1% 2.5%, of Galderma Laboratories LP.

According to IQVIA sales data for the 12 month period ending September 2019, the Epiduo Gel, 0.1% 2.5% market achieved annual sales of approximately $33.7 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceutic..
Financials More
Rs. in Millions
QTR Sep 19 ANNUAL 19
Net Profit4319.9216221.12
Gross Profit 4745.07 18181.84
Operating Profit 5729.9618030.92
Net Sales 17898.1963048.67
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 2761.55 (4.11%)
M.Cap ( in Cr)
6903.88
Sanofi India (BSE)
 7018.65 (0.70%)
M.Cap ( in Cr)
16164.39
Divis Lab (BSE)
 1806.35 (1.30%)
M.Cap ( in Cr)
47952.92
Hester Biosciences (BSE)
 1574.70 (1.33%)
M.Cap ( in Cr)
1339.58
Torrent Pharma (BSE)
 1867.95 (0.94%)
M.Cap ( in Cr)
31607.34
Shareholding Pattern More
PROMOTERS 46.58 %
MUTUAL FUNDS/UTI 4.31 %
FI/BANKS/INSURANCE 3 %
NON-INSTITUTION 14.62 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes